Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: Methodologic considerations.

[1]  Diane J Post,et al.  Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity , 2019, Vaccine.

[2]  Neal W. Dickert,et al.  The Future of Flu: A Review of the Human Challenge Model and Systems Biology for Advancement of Influenza Vaccinology , 2019, Front. Cell. Infect. Microbiol..

[3]  F. Hayden,et al.  Influenza virus polymerase inhibitors in clinical development , 2019, Current opinion in infectious diseases.

[4]  R. Finberg,et al.  Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial , 2018, The Journal of infectious diseases.

[5]  F. Hayden,et al.  Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents , 2018, The New England journal of medicine.

[6]  N. Leidy,et al.  Using the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge model , 2018, BMC Infectious Diseases.

[7]  A. Ukimura,et al.  The Prevalence and Findings of Subclinical Influenza-associated Cardiac Abnormalities among Japanese Patients , 2018, Internal medicine.

[8]  J. Taubenberger,et al.  Evaluation of Preexisting Anti-Hemagglutinin Stalk Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus , 2018, mBio.

[9]  M. Hughes,et al.  A Randomized Study of Immune Plasma for the Treatment of Severe Influenza , 2017 .

[10]  J. Tregoning,et al.  Nasal IgA Provides Protection against Human Influenza Challenge in Volunteers with Low Serum Influenza Antibody Titre , 2017, Front. Microbiol..

[11]  Z. Memish,et al.  Impact of Outpatient Neuraminidase Inhibitor Treatment in Patients Infected With Influenza A(H1N1)pdm09 at High Risk of Hospitalization: An Individual Participant Data Metaanalysis , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  A. Wilder-Smith,et al.  Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[13]  J. Powers,et al.  Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model , 2016, mBio.

[14]  A. Hurt,et al.  Using the Ferret as an Animal Model for Investigating Influenza Antiviral Effectiveness , 2016, Front. Microbiol..

[15]  S. Pocock,et al.  Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials , 2015, The Lancet.

[16]  Jonathan J Deeks,et al.  Cellular immune correlates of protection against symptomatic pandemic influenza , 2013, Nature Medicine.

[17]  J. Oxford,et al.  Clinical, scientific and ethnographic studies of influenza in quarantine , 2012, Expert review of vaccines.

[18]  P. Gilbert,et al.  Nomenclature for immune correlates of protection after vaccination. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  J. Oxford,et al.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans , 2012, Nature Medicine.

[20]  J. Oxford,et al.  Use of a human influenza challenge model to assess person-to-person transmission: proof-of-concept study. , 2011, The Journal of infectious diseases.

[21]  Weizhong Yang,et al.  Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China , 2010, BMJ : British Medical Journal.

[22]  W. Gruber,et al.  Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young Children , 2008, Clinical and Vaccine Immunology.

[23]  N. Ferguson,et al.  Time lines of infection and disease in human influenza: a review of volunteer challenge studies. , 2008, American journal of epidemiology.

[24]  A. McMichael,et al.  Cytotoxic T-cell immunity to influenza. , 1983, The New England journal of medicine.

[25]  F. Aoki,et al.  Distribution and removal of human serum albumin-technetium 99m instilled intranasally. , 1976, British journal of clinical pharmacology.

[26]  Hasleton Ps.  The internal surface area of the adult human lung. , 1972, Journal of anatomy.

[27]  R. Douglas,et al.  Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man. , 1971, The Journal of infectious diseases.

[28]  V. Knight,et al.  Human Influenza Resulting from Aerosol Inhalation , 1966, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[29]  T. Francis,et al.  PROTECTIVE EFFECT OF VACCINATION AGAINST INDUCED INFLUENZA A. , 1945, The Journal of clinical investigation.

[30]  T. Francis,et al.  Protective Effect of Vaccination Against Induced Influenza B.∗ , 1944 .

[31]  J. W. Little,et al.  Attenuated influenza produced by experimental intranasal inoculation , 1979, Journal of medical virology.

[32]  P. Hasleton.  The internal surface area of the adult human lung. , 1972, Journal of anatomy.